DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-1.07%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$2.67B
AUM Growth
+$2.67B
(-15%)
Cap. Flow
-$330M
Cap. Flow
% of AUM
-12.39%
Top 10 Holdings %
Top 10 Hldgs %
52.23%
Holding
84
New
14
Increased
17
Reduced
20
Closed
22
Top Buys
| 1 |
Cytokinetics
CYTK
|
$88M |
| 2 |
Dynavax Technologies
DVAX
|
$67.2M |
| 3 |
Harmony Biosciences
HRMY
|
$49.9M |
| 4 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$43.8M |
| 5 |
Structure Therapeutics
GPCR
|
$42.8M |
Top Sells
| 1 |
argenx
ARGX
|
$198M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$108M |
| 3 |
Intellia Therapeutics
NTLA
|
$102M |
| 4 |
Alkermes
ALKS
|
$98M |
| 5 |
Axsome Therapeutics
AXSM
|
$77M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALLK
51
DELISTED
Allakos
ALLK
| $6.9M | 0.26% | 5,704,282 +704,282 | +14% | +$852K |
|
52
Xenon Pharmaceuticals
XENE
$2.98B
| $6.63M | 0.25% | +169,132 | New | +$6.63M |
|
53
Avalo Therapeutics
AVTX
$122M
| $6.44M | 0.24% | 867,000 -100,000 | -10% | -$743K |
|
54
Inovio Pharmaceuticals
INO
$126M
| $5.71M | 0.21% | 3,119,162 +1,314,796 | +73% | +$2.41M |
|
|
RGLS
55
DELISTED
Regulus Therapeutics
RGLS
| $5.15M | 0.19% | 3,262,564 | – | – |
|
56
Spyre Therapeutics
SYRE
$996M
| $5.1M | 0.19% | 219,015 -780,985 | -78% | -$18.2M |
|
57
Invivyd
IVVD
$204M
| $4.74M | 0.18% | 10,689,603 -264,334 | -2% | -$117K |
|
|
OKUR
58
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $4.51M | 0.17% | +523,989 | New | +$4.51M |
|
59
4D Molecular Therapeutics
FDMT
$288M
| $3.4M | 0.13% | 609,900 -3,486,552 | -85% | -$19.4M |
|
|
CLYM
60
Climb Bio, Inc. Common Stock
CLYM
$151M
| $1.87M | 0.07% | 1,040,115 -1,129,028 | -52% | -$2.03M |
|
61
Nektar Therapeutics
NKTR
$568M
| $1.84M | 0.07% | 1,975,998 -13,946,657 | -88% | -$13M |
|
62
Alector
ALEC
$238M
| – | – | -4,631,998 | Closed | -$21.6M |
|
|
63
Alkermes
ALKS
$4.78B
| – | – | -3,500,000 | Closed | -$98M |
|
64
Apogee Therapeutics
APGE
$2.17B
| – | – | -1,000,000 | Closed | -$58.7M |
|
|
65
argenx
ARGX
$43.6B
| – | – | -365,000 | Closed | -$198M |
|
|
66
Axsome Therapeutics
AXSM
$6.05B
| – | – | -857,219 | Closed | -$77M |
|
67
Editas Medicine
EDIT
$231M
| – | – | -4,900,334 | Closed | -$16.7M |
|
68
Fate Therapeutics
FATE
$120M
| – | – | -5,572,607 | Closed | -$19.5M |
|
69
Kura Oncology
KURA
$686M
| – | – | -1,963,505 | Closed | -$38.4M |
|
70
Kymera Therapeutics
KYMR
$2.95B
| – | – | -600,326 | Closed | -$28.4M |
|
|
71
Intellia Therapeutics
NTLA
$1.22B
| – | – | -4,950,000 | Closed | -$102M |
|
72
Prothena Corp
PRTA
$441M
| – | – | -140,000 | Closed | -$2.34M |
|
73
Pyxis Oncology
PYXS
$79.4M
| – | – | -4,184,100 | Closed | -$15.4M |
|
74
Relmada Therapeutics
RLMD
$37.2M
| – | – | -674,833 | Closed | -$2.19M |
|
75
Avidity Biosciences
RNA
$5.99B
| – | – | -475,000 | Closed | -$21.8M |
|